Johnson & Johnson
JNJ
253.79
-1.77
-0.69%
Johnson & Johnson
US · JNJ
#25 by market cap
Listed 1970
253.79
-1.77
-0.69%
Live - 5344 symbols - heartbeat 141s ago
· 2026-10-20 06:32
Revenue annual, last 8 years
Latest year +6.05% YoY
Margins
- Gross margin
- 67.88%
- Operating margin
- 27.17%
- Net margin
- 28.46%
Key ratios & quality
- Enterprise valuei
- 639.44B
- PEG ratioi
- 2.69
PEG uses trailing P/E against the 3-year net income growth rate (14.32%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG."
Income statement
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 81.58B | 82.06B | 82.58B | 78.74B | 79.99B | 85.16B | 88.82B | 94.19B |
| Gross profit | 54.49B | 54.50B | 54.16B | 55.34B | 55.39B | 58.61B | 61.35B | 63.94B |
| Selling & admin expenses | 22.54B | 22.18B | 22.08B | 20.12B | 20.25B | 21.51B | 22.87B | 23.68B |
| Research & development | 10.78B | 11.36B | 12.16B | 14.28B | 14.14B | 15.09B | 17.23B | 14.67B |
| Operating profit | 21.18B | 20.97B | 19.91B | 20.94B | 21.01B | 22.01B | 21.25B | 25.60B |
| Pretax profit | 18.00B | 17.33B | 16.50B | 19.18B | 19.36B | 15.06B | 16.69B | 32.58B |
| Tax | 2.70B | 2.21B | 1.78B | 1.38B | 2.99B | 1.74B | 2.62B | 5.78B |
| Net profit | 15.30B | 15.12B | 14.71B | 20.88B | 17.94B | 35.15B | 14.07B | 26.80B |
| Basic EPS | 6 | 6 | 6 | 8 | 7 | 14 | 6 | 11 |
| Diluted EPS | 5.61 | 5.63 | 5.51 | 7.81 | 6.73 | 13.72 | 5.79 | 11.03 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 23.74B | 23.99B | 24.56B | 24.06B | 25.31B | 25.40B |
| Gross profit | 16.12B | 16.69B | 16.60B | 15.96B | 17.26B | 17.30B |
| Selling & admin expenses | 5.89B | 5.92B | 6.75B | 6.03B | 6.43B | 6.29B |
| Research & development | 3.52B | 3.67B | 4.25B | 3.53B | 3.65B | 4.65B |
| Operating profit | 6.71B | 7.10B | 5.59B | 6.40B | 7.17B | 6.37B |
| Pretax profit | 6.49B | 7.49B | 4.97B | 5.99B | 6.75B | 34.00M |
| Tax | 954.00M | 2.34B | -150.00M | 755.00M | 1.21B | -176.00M |
| Net profit | 5.54B | 5.15B | 5.12B | 5.24B | 5.53B | 210.00M |
| Basic EPS | 2 | 2 | 2 | 2 | 2 | 0 |
| Diluted EPS | 2.29 | 2.12 | 2.10 | 2.14 | 2.27 | 0.09 |
Balance sheet
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 46.03B | 45.27B | 51.24B | 60.98B | 55.29B | 53.50B | 55.89B | 55.62B |
| Cash & ST investments | 19.69B | 19.29B | 25.19B | 31.61B | 22.28B | 22.93B | 24.52B | 20.10B |
| Inventory | 8.60B | 9.02B | 9.34B | 10.39B | 10.27B | 11.18B | 12.44B | 14.19B |
| Total assets | 152.95B | 157.73B | 174.89B | 182.02B | 187.38B | 167.56B | 180.10B | 199.21B |
| Total current liabilities | 31.23B | 35.96B | 42.49B | 45.23B | 55.80B | 46.28B | 50.32B | 54.13B |
| Short-term debt | 2.80B | 1.20B | 2.63B | 3.77B | 12.76B | 3.45B | 5.98B | 8.50B |
| Long-term debt | 27.68B | 26.49B | 32.64B | 29.99B | 26.89B | 25.88B | 30.65B | 39.44B |
| Total liabilities | 93,202,000,000.00 | 98,257,000,000.00 | 111,616,000,000.00 | 107,995,000,000.00 | 110,574,000,000.00 | 98,784,000,000.00 | 108,614,000,000.00 | 117,666,000,000.00 |
| Total equity | 59.75B | 59.47B | 63.28B | 74.02B | 76.80B | 68.77B | 71.49B | 81.54B |
| Retained earnings | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 54.50B | 54.61B | 55.62B | 59.17B | 59.77B | -- |
| Cash & ST investments | 18.88B | 18.56B | 20.10B | 22.05B | 20.76B | -- |
| Inventory | 13.41B | 14.15B | 14.19B | 14.58B | 15.14B | -- |
| Total assets | 193.39B | 192.82B | 199.21B | 200.89B | 201.06B | -- |
| Total current liabilities | 54.18B | 50.87B | 54.13B | 57.72B | 54.90B | -- |
| Short-term debt | 11.53B | 6.39B | 8.50B | 17.46B | 11.69B | -- |
| Long-term debt | 39.24B | 39.41B | 39.44B | 37.53B | 37.34B | -- |
| Total liabilities | 114,916,000,000.00 | 113,539,000,000.00 | 117,666,000,000.00 | 119,708,000,000.00 | 116,090,000,000.00 | -- |
| Total equity | 78.47B | 79.28B | 81.54B | 81.19B | 84.97B | -- |
| Retained earnings | -- | -- | -- | -- | -- | -- |
Cash flow
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 22.20B | 23.42B | 23.54B | 23.41B | 21.19B | 22.79B | 24.27B | 24.53B |
| Depreciation & amortization | 6.93B | 7.01B | 7.23B | 7.39B | 6.97B | 7.49B | 7.34B | 7.50B |
| Free cash flow | 18.53B | 19.92B | 20.19B | 19.76B | 17.19B | 17.78B | 18.06B | 19.31B |
| Dividends paid | -9.49B | -9.92B | -10.48B | -11.03B | -11.68B | -11.77B | -11.82B | -12.38B |
| Stock buybacks / issuance | -5.87B | -6.75B | -3.22B | -3.46B | -6.04B | -813.00M | -2.43B | -5.95B |
| Ending cash balance | 18.11B | 17.31B | 13.99B | 14.49B | 14.13B | 21.86B | 24.11B | 19.71B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 3.88B | 9.17B | 7.31B | 2.51B | 8.62B | -- |
| Depreciation & amortization | 1.94B | 1.78B | 2.01B | 2.00B | 1.96B | -- |
| Free cash flow | 2.48B | 8.00B | 5.47B | 1.47B | 7.30B | -- |
| Dividends paid | -3.13B | -3.13B | -3.13B | -3.13B | -3.23B | -- |
| Stock buybacks / issuance | 0 | -1.90B | -1.92B | -4.03B | -221.00M | -- |
| Ending cash balance | 18.58B | 18.23B | 19.71B | 21.69B | 20.42B | -- |
Returns & efficiency
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 25.51 | 25.36 | 23.97 | 30.41 | 23.79 | 48.29 | 20.06 | 35.03 |
| ROA %i | 9.86 | 9.73 | 8.85 | 11.70 | 9.71 | 19.81 | 8.09 | 14.13 |
| ROIC %i | 16.90 | 17.01 | 15.93 | 20.35 | 15.84 | 32.36 | 13.17 | 22.50 |
| 5-year avg ROE %i | 19.09 | 19.62 | 20.04 | 21.45 | 25.81 | 30.37 | 29.31 | 31.52 |
| EBIT margin %i | 23.29 | 21.50 | 20.22 | 24.48 | 23.17 | 18.59 | 19.64 | 35.62 |
| FCF / sales %i | 22.71 | 24.27 | 24.45 | 21.07 | 18.10 | 20.88 | 20.33 | 20.50 |
| Current ratioi | 1.47 | 1.26 | 1.21 | 1.35 | 0.99 | 1.16 | 1.11 | 1.03 |
| Quick ratioi | 1.08 | 0.94 | 0.91 | 1.12 | 0.70 | 0.91 | 0.86 | 0.77 |
| Debt / assetsi | 19.93 | 17.56 | 20.16 | 18.54 | 21.16 | 17.51 | 20.34 | 24.06 |
| LT debt / equityi | 46.33 | 44.55 | 51.57 | 40.51 | 35.01 | 37.63 | 42.87 | 48.36 |
| Interest coveragei | 18.91 | 55.49 | 83.07 | 125.46 | 79.71 | 20.51 | 23.10 | 34.55 |
| Revenue CAGR (3Y) %i | 5.20 | 4.51 | 2.61 | -1.17 | -0.85 | 1.03 | 4.10 | 5.60 |
| Net income CAGR (3Y) %i | -0.24 | -2.95 | 124.52 | 10.92 | 5.87 | 33.68 | -12.33 | 14.32 |
| FCF CAGR (3Y) %i | 4.79 | 8.62 | 4.33 | 2.16 | -4.80 | -4.15 | -2.95 | 3.97 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | 30.21 | 33.62 | 35.03 | 26.42 | 25.74 | -- |
| ROA %i | 12.10 | 13.54 | 14.13 | 10.66 | 10.67 | -- |
| ROIC %i | 18.49 | 21.61 | 22.50 | 15.84 | 16.05 | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 31.10 | 35.16 | 35.62 | 26.96 | 26.76 | 25.28 |
| FCF / sales %i | 18.09 | 20.27 | 20.50 | 18.07 | 22.70 | -- |
| Current ratioi | 1.01 | 1.07 | 1.03 | 1.03 | 1.09 | -- |
| Quick ratioi | 0.68 | 0.71 | 0.77 | 0.77 | 0.73 | -- |
| Debt / assetsi | 26.25 | 23.75 | 24.06 | 27.37 | 24.39 | -- |
| LT debt / equityi | 50.00 | 49.71 | 48.36 | 46.22 | 43.95 | -- |
| Interest coveragei | 33.48 | 36.24 | 34.55 | 25.00 | 25.90 | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Innovative Medicine is the largest reported line at 64.73% of revenue, across 2 reported segments.
- MedTech follows at 35.27%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Innovative Medicine64.73%
MedTech35.27%
Quote time 2026-10-20 06:32:51 · For reference only, not investment advice and not tailored to your situation.
talc litigation headlines still spook this stock every few months but the pharma pipeline keeps quietly delivering. slow and steady, exactly how I like my healthcare names.